景兴纸业(002067) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was CNY 1,303,670,898.29, representing a 50.90% increase compared to CNY 863,934,840.71 in the same period last year[8] - Net profit attributable to shareholders was CNY 116,388,623.13, a significant increase of 168.32% from CNY 43,376,001.33 year-on-year[8] - The net profit after deducting non-recurring gains and losses reached CNY 114,166,854.53, marking a 378.95% increase compared to CNY 23,837,025.99 in the previous year[8] - The basic earnings per share increased to CNY 0.10, up 150.00% from CNY 0.04 in the same quarter last year[8] - The diluted earnings per share rose to CNY 0.09, reflecting a 125.00% increase from CNY 0.04 year-on-year[8] - Total revenue increased by 50.90% year-on-year, while operating costs rose by 41.94%, primarily due to increased product sales[16] - The total profit for the period was CNY 141,967,085.69, significantly higher than CNY 45,885,918.01 in Q1 2020, marking a growth of 209.5%[46] - The total profit margin improved, with a profit margin of approximately 15.0% in Q1 2021 compared to 7.4% in Q1 2020[46] Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 7,379,402,853.68, a 1.20% increase from CNY 7,291,734,218.26 at the end of the previous year[8] - The net assets attributable to shareholders increased to CNY 5,020,065,596.22, which is a 5.43% rise from CNY 4,761,717,345.78 at the end of the last year[8] - The company's total assets as of March 31, 2021, amounted to CNY 6,035,209,501.39, slightly up from CNY 5,985,717,015.07 at the end of 2020[41] - The total liabilities decreased to CNY 1,510,589,058.03 in Q1 2021 from CNY 1,705,433,048.04 in the previous period[42] Cash Flow - The net cash flow from operating activities was CNY -43,757,216.28, an improvement of 29.65% compared to CNY -62,195,655.32 in the same period last year[8] - The cash flow from operating activities was CNY 1,228,216,437.43, compared to CNY 944,002,427.60 in the previous period, showing a significant increase[53] - Operating cash inflow totaled CNY 1,247,409,694.64, an increase from CNY 987,490,851.47 in the previous period[54] - Net cash flow from operating activities was negative CNY 43,757,216.28, improving from negative CNY 62,195,655.32 year-over-year[54] - Net cash flow from investment activities was negative CNY 69,301,276.66, worsening from negative CNY 24,092,584.94 year-over-year[54] - Net cash flow from financing activities was negative CNY 46,097,425.08, compared to a positive CNY 132,019,975.05 in the prior year[55] Shareholder Information - The total number of shareholders at the end of the reporting period was 81,370[12] - The company is committed to fulfilling its promises to minority shareholders, ensuring transparency and accountability[22] - There were no share buybacks or reductions in shareholding during the reporting period[21] Investments and Projects - The company raised a total of CNY 1.28 billion through the issuance of convertible bonds, with a net amount of CNY 1.262 billion after deducting issuance costs[26] - The company has invested CNY 67.42 million in the first phase of its 1.4 million tons project in Malaysia, with a cumulative investment of CNY 498.93 million as of the end of the reporting period[26] - The company completed the transfer of 100% equity in Xiangyu Pharmaceutical, receiving a total of 34.64 million yuan[17] Government Subsidies and Tax Incentives - The company received a total of government subsidies amounting to approximately 10.64 million yuan during the reporting period[19] - The company received a tax refund of CNY 3,310,856.87 related to labor value-added tax incentives[21] - A total of CNY 1,477,459.24 was received from resource comprehensive utilization product tax refunds during the quarter[21] - The company reported a subsidy of CNY 806,400.00 aimed at promoting employment for disabled individuals[21] - The company is actively pursuing various tax incentives and subsidies to enhance its financial performance[21] Research and Development - Research and development expenses for Q1 2021 were CNY 50,737,870.84, slightly higher than CNY 49,153,971.96 in Q1 2020[45] - Research and development expenses increased to CNY 32,109,449.65, up 29.1% from CNY 24,857,710.88 in the previous year[49] Other Financial Information - The company's cash and cash equivalents decreased to CNY 1.415 billion from CNY 1.576 billion at the end of 2020[36] - The company's equity attributable to shareholders rose to CNY 5,020,065,596.22 from CNY 4,761,717,345.78 in the previous period[39] - The company reported a decrease in other comprehensive income, with a loss of CNY 30,662,344.98 in Q1 2021 compared to a loss of CNY 17,359,703.17 in the previous period[39] - The company has not engaged in any securities or derivative investments during the reporting period[24][25] - There were no instances of non-operating fund occupation by controlling shareholders or related parties during the reporting period[29] - The company did not undergo an audit for the first quarter report[60]